← Eichor
Condition: Metastatic Bladder Urothelial Carcinoma Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Bladder Urothelial Carcinoma

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Sacituzumab Govitecan Plus EV in Metastatic UC
Phase 1/Phase 2 · 1 location(s) · Dana-Farber Cancer Institute · NCT04724018Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
Phase 2 · 1 location(s) · Mayo Clinic · NCT07087860Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Phase 1 · 1 location(s) · Emory University · NCT04878029Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT04235777Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
Phase N/A · 1 location(s) · Dana-Farber Cancer Institute · NCT06138561SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 · 12 location(s) · Aktis Oncology, Inc. · NCT07020117A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Phase 1 · 30 location(s) · Pfizer · NCT07090499Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
Phase 1 · 1 location(s) · Beijing Biotech · NCT07492628A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Phase 2 · 221 location(s) · Seagen, a wholly owned subsidiary of Pfizer · NCT04879329A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Phase 3 · 286 location(s) · Eli Lilly and Company · NCT07218380Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours
Phase 4 · 1 location(s) · University of Roma La Sapienza · NCT05962541Intervention of Bladder Cancer by CAR-T
Phase 1/Phase 2 · 1 location(s) · Shenzhen Geno-Immune Medical Institute · NCT03185468FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3
Phase 1 · 82 location(s) · Eli Lilly and Company · NCT05614739A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 · 16 location(s) · IDEAYA Biosciences · NCT07277413KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People
Phase 1/Phase 2 · 16 location(s) · Merck Sharp & Dohme LLC · NCT07232602Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Loc
Phase 1/Phase 2 · 18 location(s) · Aulos Bioscience, Inc. · NCT05267626Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Phase 1/Phase 2 · 1 location(s) · Hadassah Medical Organization · NCT05296564A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
Phase 1 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05562791Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Phase 2/Phase 3 · 1 location(s) · Vasgene Therapeutics, Inc · NCT064935529MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 · 2 location(s) · Mabwell (Shanghai) Bioscience Co., Ltd. · NCT06823427A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
Phase 3 · 71 location(s) · Merck Sharp & Dohme LLC · NCT07419295Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Phase 1/Phase 2 · 115 location(s) · Pfizer · NCT07421700Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothe
Phase 2 · 2 location(s) · Northwestern University · NCT06630416A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and
Phase 4 · 1 location(s) · Mayo Clinic · NCT06764095Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Phase N/A · 3 location(s) · Mayo Clinic · NCT06349642Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabo
Phase 2 · 582 location(s) · National Cancer Institute (NCI) · NCT03866382Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Partic
Phase 2/Phase 3 · 100 location(s) · Daiichi Sankyo · NCT07129993Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/
Phase N/A · 1 location(s) · University of Washington · NCT01050504
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.